Prelude Therapeutics (PRLD) Assets Average (2020 - 2026)

Prelude Therapeutics (PRLD) has 7 years of Assets Average data on file, last reported at $130.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 17.62% year-over-year to $130.5 million; the trailing twelve-month figure through Mar 2026 stood at $130.5 million (down 17.62% YoY), and the FY2025 full-year result was $158.4 million, down 30.09% from the prior year.
• Assets Average improved to $130.5 million in Q1 2026, from $118.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $292.9 million in Q1 2022 to a low of $104.8 million in Q3 2025.
• A 5-year average of $209.8 million and a median of $231.4 million in 2022 frame the typical range for Assets Average.
• Across the five-year window, Assets Average advanced 25.3% in 2024 and sank 50.26% in 2025, its largest moves.
• Tracing PRLD's Assets Average over 5 years: stood at $231.4 million in 2022, then climbed by 15.85% to $268.1 million in 2023, then plunged by 30.48% to $186.4 million in 2024, then tumbled by 36.67% to $118.0 million in 2025, then gained by 10.54% to $130.5 million in 2026.
• Business Quant data shows PRLD's Assets Average at $130.5 million in Q1 2026, $118.0 million in Q4 2025, and $104.8 million in Q3 2025.